QLT Gets New Lease On Life With Multi-Pronged Deals
Executive Summary
The Canadian drug developer will be in a position to advance its lead retinoid asset and be an acquirer of choice, according to management, after completing a series of deals, including the acquisition of InSite Vision and an investment in a new company, Aralez Pharmaceuticals.
You may also be interested in...
QLT Shows Off Its Assets In Hopes Of Attracting A Suitor
The Canadian biotech has put itself on the block after a year of changes that have transformed the company from a commercial-stage entity with pipeline assets to a one-drug tax play.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.